@gooo_tw_'s TRT promotion video lacks medical substance

What did @gooo_tw_ actually say?

The creator pushed back against a growing TikTok consensus that testosterone isocaproate ("tisochron") is definitively superior to cypionate, citing a study by Kurt Haven. Their core argument: don't get emotionally attached to a single ester based on one small-sample study. They also invoked genetics, specifically how quickly an individual cleaves an ester via enzymes like PDE7, and argued the only real test is personal trial. That last bit deserves scrutiny.

The framing is more measured than most TRT content. They're not selling isocaproate or cypionate. They're arguing for epistemic humility, which is a reasonable position. But the mechanism they cite, PDE7 as an esterase responsible for cleaving testosterone esters, is where things get clinically fuzzy.

Does the science back this up?

Partially, but the mechanism claim is off. Testosterone esters are hydrolyzed primarily by non-specific esterases and carboxylesterases in serum and liver tissue, not PDE7. PDE7 is a phosphodiesterase that breaks down cyclic AMP. It has no established role in ester hydrolysis. That said, the broader point about individual pharmacokinetic variability is well-supported.

A 2021 paper by Nieschlag and Behre in the European Journal of Endocrinology confirms that serum testosterone peaks, troughs, and clearance rates vary meaningfully between individuals on the same ester and dose. The Haven study the creator references appears to be a small pharmacokinetic comparison, and small-n PK studies do have real limitations for generalizing clinical outcomes. The creator is right that one underpowered study shouldn't overturn years of clinical experience. That's basic evidence hierarchy, and they stated it correctly.

What did they get wrong (or right)?

The PDE7 claim is wrong and it matters. Telling an audience that "higher PDE7 cleaves off the ester" is not supported by current endocrine pharmacology literature. Ester hydrolysis is mediated by serum esterases, not phosphodiesterases. This is the kind of technical error that sounds credible because it uses real biochemical vocabulary, but it points in the wrong direction. If someone repeats this to their prescriber, it creates confusion.

What they got right: the call for caution about small sample sizes is legitimate. N=small PK studies are routinely overclaimed on social media. They also correctly note that isocaproate and cypionate have different half-lives and serum peak profiles, which is accurate. Testosterone isocaproate has a shorter half-life than cypionate, roughly 9 days versus 8 days respectively, though both fall in a similar range and clinical significance of that difference is debated.

• Wrong: PDE7 as the ester-cleaving enzyme
• Right: Sample size caveat on the Haven study
• Right: Individual variability affects ester response
• Unverifiable: That personal trial is the "only way" to know

What should you actually know?

The ester debate in TRT is mostly a distraction from the variables that matter more: injection frequency, total weekly dose, individual metabolism, and SHBG levels. A 2020 review by Ramasamy et al. in Translational Andrology and Urology found that symptom resolution in hypogonadal men correlates more with trough levels and consistency of administration than with which specific ester is used.

"Trying it out for yourself" is not bad advice in principle. Switching esters under medical supervision while tracking labs and symptoms is a reasonable clinical approach. But it is not a substitute for pharmacokinetic data, and framing it that way understates how long it takes to reach steady state on any ester, typically 4 to 5 half-lives. Informal self-experimentation without structured lab monitoring produces noisy, uninterpretable results for most people.

If you are on a TRT protocol and curious about ester differences, the conversation belongs with your prescribing clinician, not a TikTok comment section.

Bottom line

This video lands somewhere between reasonable and sloppy. The overall message, that one small study shouldn't trigger a mass ester switch, is defensible. The execution includes at least one clear biochemical error that undermines the credibility of the rest. Watch with appropriate skepticism.